



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Mizolastine

Item No. 9000566

CAS Registry No.: 108612-45-9
Formal Name: 2-[[1-[1-(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-4-piperidinyl]methylamino]-4(3H)-pyrimidinone
Synonym: SL 850324
MF: C₂₄H₂₅FN₆O
FW: 432.5
Purity: ≥98%
UV/Vis.: λ_{max}: 217, 289 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Mizolastine is supplied as a crystalline solid. A stock solution may be made by dissolving the mizolastine in the solvent of choice, which should be purged with an inert gas. Mizolastine is soluble in the organic solvent chloroform at a concentration of approximately 10 mg/ml. Mizolastine is also slightly soluble in DMSO and dimethyl formamide.

Description

Mizolastine is a histamine H₁ receptor antagonist (K_i = 0.001 μM).¹ It is selective for histamine H₁ over histamine H₂ and H₃ receptors (K_s = >100 μM for both), as well as the serotonin (5-HT) receptor subtypes 5-HT_{1A}, 5-HT_{1B}, 5-HT_{1C}, 5-HT_{1D}, 5-HT₂, and 5-HT₃, dopamine D₁ and D₂, α₁- and α₂-adrenergic, adenosine, and muscarinic receptors in radioligand binding assays (K_s = >1 μM for all). Mizolastine (0.1, 0.3, and 1 mg/kg) reduces histamine release from bronchial mast cells in ovalbumin-sensitized guinea pigs. It reduces histamine-induced paw edema in rats, skin edema in dogs, and bronchoconstriction in guinea pigs (ED₅₀s = 0.5, 0.07, and 0.03 mg/kg, respectively). Mizolastine also inhibits passive cutaneous anaphylaxis, as well as lethal shock induced by compound 48/80 (Item No. 22173) in rats (ED₅₀s = 1.6 and 0.07 mg/kg, respectively). Formulations containing mizolastine have been used in the treatment of allergic rhinitis and urticaria.

Reference

1. Selve, N., Pichat, P., Goldhill, J., *et al.* Pharmacological profile of mizolastine, a novel histamine H₁ receptor antagonist. *Mast cells and basophils*. Moore, G., Lichtenstein, L.M., Galli, S.J., editors, 1st edition, Academic Press (2000).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/10/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM